Table 4 The levels of cartilage markers in the synovial fluid, plasma, and urine of OA patients or control groups
Concentration, mean (95% CI) | P-value | ROC analysis (controls versus knee OA patients) | |||||||
|---|---|---|---|---|---|---|---|---|---|
Control | Knee OA | AUC | 95% CI | P-value | Cut-off | Sensitivity | Specificity | ||
pCOMP, ng/ml | 80.0 (64.1–96.0) | 114.5 (87.9–141.1) | 0.165 | ||||||
pCTX-II, ng/ml | 0.6 (0.3–0.9) | 0.7 (0.5–0.9) | 0.388 | ||||||
pHA, ng/ml | 23.3 (0.2–46.4) | 55.4 (30.3–80.5) | 0.004** | 0.81 | 0.62–1.00 | 0.006** | 20.3 | 0.77 | 0.89 |
pMMP-1, ng/ml | 1.2 (−0.1–2.6) | 0.9 (0.5–1.3) | 0.903 | ||||||
pMMP-3, ng/ml | 13.5 (9.6–17.4) | 15.0 (10.7–19.3) | 0.520 | ||||||
uCOMP, pg/ml | 1.0 (−0.2–2.2) | 5.8 (3.7–7.9) | < 0.0001*** | 0.95 | 0.85–1.00 | 0.0003*** | 1.1 | 1.00 | 0.87 |
uCTX-II, pg/ml | 5.5 (2.2–8.8) | 25.1 (12.4–37.7) | 0.001** | 0.89 | 0.76–1.00 | 0.002** | 5.4 | 0.96 | 0.57 |
uHA, pg/ml | 25.2 (14.4–36.0) | 256.9 (192.9–320.9) | < 0.0001*** | 1.00 | 1.00–1.00 | < 0.0001*** | 52.8 | 1.00 | 1.00 |
uMMP-1, pg/ml | NA | NA | |||||||
uMMP-3, pg/ml | 0.5 (0.2–0.8) | 3.5 (1.2–5.7) | < 0.0001*** | 0.97 | 0.91–1.00 | 0.0002*** | 0.9 | 0.88 | 1.00 |
sfCOMP, ng/ml | – | 4553.6 (3557.8–5549.3) | |||||||
sfCTX-II, ng/ml | – | 2.6 (2.3–3.0) | |||||||
sfHA, ng/ml | – | 1314.5 (1238.0–1391.1) | |||||||
sfMMP-1, ng/ml | – | 30.0 (15. 8–44.2) | |||||||
sfMMP-3, ng/ml | – | 319.8 (285.5–354.0) | |||||||